Incyte's oral JAK inhibitor povorcitinib achieved primary endpoints in two Phase 3 trials (STOP-V1 and STOP-V2) for nonsegmental vitiligo in adults1
Both trials met the primary endpoint of more than 75% reduction in facial vitiligo score at week 52, with 18.9% of povorcitinib-treated patients reaching this threshold compared to 6.8% and 3.1% in the respective control groups1
The 30 mg dose of povorcitinib demonstrated statistically significant and clinically meaningful improvements in secondary endpoints, including 50% or greater reduction in body vitiligo1
Povorcitinib did not achieve results comparable to AbbVie's Rinvoq, indicating competitive positioning in the vitiligo treatment market1
The company plans to file for regulatory approval based on these Phase 3 results1
Sources:
1. https://www.fiercebiotech.com/biotech/incytes-jak-inhibitor-scores-phase-3-vitiligo-wins-cant-quite-shake-rinvoq